NEW YORK, Jan 16 – Bayer said Tuesday it had agreed to make an $85 million equity investment in CuraGen as well as provide an additional $39 million in funding in exchange for Curagen’s commitment to use its functional genomics tools to evaluate the pharmaceutical giant’s early-stage pipeline of compounds.

The collaboration is an expandable, five-year deal.

In addition, the companies also announced plans to work together to discover and commercialize small molecule drugs for treating obesity and adult onset diabetes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A draft bill released by the US House of Representatives appropriations committee would increase the 2019 National Institutes of Health budget by 3 percent.

Bloomberg looks into privacy issues raised by law enforcement's use of genetic genealogy sites.

NBC News reports on the Earth BioGenome Project, which aims to sequence all eukaryotic life on Earth.

In Science this week: environmental DNA can help in studies of marine animals, and more.